Nexell 128% Plus!!! - 500 Beiträge pro Seite

[Newman8]

Ist Nexell nun doch gerettet?,oder ist es nur ein Zock?
Das Volumen war heute aber echt groß!!!
Hat denn Niemannd eine Info?
Danke Newmann8

[Newman8]

66 Gelesen,und keiner einen Plan? :-(
Naja,eventuell ja morgen!
N8
Newmann8

[JS222]

Scheint ein ZOCK zu sein ASKs nach Ablauf sehr hoch !!!!!!5:03:47 PM Bid 0.15 5000 Nasdaq NM
5:02:09 PM Ask 0.18 40000 Nasdaq NM
5:02:07 PM Ask 0.19 2500 Nasdaq NM
5:01:06 PM Ask 0.19 42500 Nasdaq NM
4:59:59 PM Ask 0.19 2500 Nasdaq NM
4:53:57 PM Ask 0.2 55000 Nasdaq NM
4:52:39 PM Bid 0.17 100 Nasdaq NM
4:52:38 PM Bid 0.15 10000 Nasdaq NM
4:51:40 PM Bid 0.15 10100 Nasdaq NM
4:50:08 PM Bid 0.15 5100 Nasdaq NM
4:50:03 PM Bid 0.15 200 Nasdaq NM
4:49:58 PM Bid 0.18 2000 Nasdaq NM
4:48:28 PM Ask 0.2 15000 Nasdaq NM
4:48:28 PM Ask 0.2 10000 Nasdaq NM
4:48:28 PM Bid 0.19 100 Nasdaq NM
4:45:34 PM Ask 0.22 5100 Nasdaq NM
5:19:19 PM Ask 0.19 6400 Nasdaq NM
5:19:19 PM Bid 0.16 5000 Nasdaq NM
5:19:19 PM Ask 0.19 1000 Nasdaq NM
5:19:19 PM Bid 0.16 8800 Nasdaq NM
5:19:18 PM Ask 0.23 1000 Nasdaq NM
5:17:25 PM Bid 0.19 8800 Nasdaq NM
5:17:25 PM Bid 0.19 7700 Nasdaq NM
5:17:25 PM Ask 0.2 15000 Nasdaq NM
5:17:02 PM Ask 0.18 1100 Nasdaq NM
5:17:00 PM Ask 0.2 15000 Nasdaq NM
5:15:33 PM Bid 0.15 10000 Nasdaq NM
5:10:45 PM Bid 0.16 5000 Nasdaq NM
5:08:31 PM Bid 0.18 2000 Nasdaq NM
5:08:31 PM Ask 0.19 2500 Nasdaq NM
5:08:29 PM Bid 0.16 5000 Nasdaq NM
5:07:55 PM Bid 0.17 7000 Nasdaq NM
5:06:41 PM Ask 0.18 5000 Nasdaq NM
5:06:25 PM Bid 0.16 5000 Nasdaq NM
5:04:14 PM Ask 0.17 1100 Nasdaq NM
5:03:47 PM Bid 0.15 5000 Nasdaq NM


JS200

[JS222]

08/15/2002 (19:15 ET) The Orange County Register, Calif., Earnings Briefs - Knight Ridder
08/14/2002 (16:35 ET) New 10-Q just released for NEXL - Edgar
08/14/2002 (16:35 ET) New 8-K just released for NEXL - Edgar
08/14/2002 (07:32 ET) Nexell Therapeutics Announces Second Quarter Results and Status of Wind Down; $33.6 Million Asset Impairment Charge Recorded As a Result of Wind Down - Business Wire


JS200

[xoma]

Ich glaube nicht an einen Zock - entweder kommt es zu einer Übernahme oder die haben einen Investor gefunden.
Die haben interessante Produkte in der Pipeline und es wird auch langsam Zeit, dass da mal eine Entscheidung kommt. Hoffe heute auf weitere +300%, denn das ist bei NEXL nichts ungewöhnliches.

[xoma]

! +157% ist ja echt super !

Name
Nexell Therapeu
Last Price
0.1800
Net Change
+0.1100
+0.0100 (AH)
Shares Matched
289,993
47,570 (AH)
Percent Change
+157.14%
+5.88 (AH)
Shares Entered
1,393,125
559,433 (AH)



Der Briefkurs steht bei 0,23, die Party geht heute weiter !

WKN 615798
Börse Nasdaq Stock Market
Symbol NEXL.NAS

Aktuelle Daten 28.08.2002
Aktueller Kurs 0,17
Kurszeit 28.08., 00:40
Differenz +0,10 (+142,86%)
Geldkurs 0,15
Geld-Zeit 00:28, 28.08.
Geld-Volumen (St.) 4.900
Briefkurs 0,23
Brief-Zeit 00:28, 28.08.
Brief-Volumen (St.) 3.500

[JS222]

VON GESTERN

NEXL
NEXELL THERAPUTICS INC
0.170
+0.100 +142.86%


Daily Commentary
WAIT

Our system recommends WAIT as of today. Previous SELL recommendation was made on 7/17/2002 (41) days ago, when the stock price was 0.110. Since then the stock gained 54.55% .

Today the stock closed higher, close to its high (sign of strength) with a higher high and an unchanged low. The volume is extremely high. The security price is trending sideways.



Candlestick Analysis


Today’s Candlestick Patterns:
Long White Candlestick


Today a Long White Candlestick formed. Buyers were aggressive and the buying pressure was strong. Be careful, this may be a potential turning point!


Stock Quote
Last 0.170
Previous Close 0.070
Change +0.100
% Change +142.86%
Volume 865,400
Stock Activity
Open 0.080
Day`s High 0.180
Day`s Low 0.070
52 Week High 2.400
52 Week Low 0.060


Stock Price History
3 Month % Change 30.77
6 Month % Change -85.95
12 Month % Change -89.10
Stock Statistics
50 Day Close MA 0.090
200 Day Close MA 0.723
65 Day Volume MA 148,728

JS200

[luto9]

Nexell Therapeutics Receives Nasdaq Delisting Notice
8/28/02



IRVINE, Calif., Aug 28, 2002 (BUSINESS WIRE) --
Nexell Therapeutics Inc. (Nasdaq:NEXL) announced that it received a letter dated August 23, 2002 from The Nasdaq Stock Market indicating that the Company fails to comply with the $1.00 minimum bid price and $5,000,000 market value of publicly-held shares requirements for continued listing set forth in Marketplace Rules 4450(a)(5) and 4450(a)(2), and, as a result, the Company`s securities -- consisting of its common stock and its publicly-traded warrants (Nasdaq:NEXLW) -- will be delisted from The Nasdaq National Market at the opening of business on September 3, 2002. The failure of the common stock to meet the minimum bid price was first announced by the Company on May 23, 2002.

The Company believes it meets the eligibility criteria to have its securities quoted on the OTC Bulletin Board (OTCBB), and the securities may be quoted on the OTCBB following delisting from the Nasdaq National Market. The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter securities. Information regarding the OTCBB can be found on the internet at www.otcbb.com.

Nexell Therapeutics Inc.

Located in Irvine, California, Nexell Therapeutics Inc. (Nasdaq:NEXL) is a biotechnology company that was focused on the modification or enhancement of human immune function and blood cell formation utilizing adult hematopoietic (blood-forming) stem cells and other specially prepared cell populations. Nexell was developing proprietary cell-based therapies that address major unmet medical needs, including treatments for genetic blood disorders, autoimmune diseases, and cancer. The Company is currently in the process of winding down operations.

The statement that the Company`s securities may be quoted on the OTC Bulletin Board constitutes a forward-looking statement within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to certain risks and uncertainties over which the Company may have no control, such as the failure of market makers to register to quote the Company`s securities on the OTCBB. The Company undertakes no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Nexell Therapeutics Inc., Irvine
Wayne A. Tyo, 949/470-9011

http://www.businesswire.com

Today`s News On The Net - Business Wire`s full file on

[Newman8]

Hi @ all
Komme gerade von der Arbeit.Es besteht ja doch Interesse an Nexell! Schön!
Kann mir jemannd den Beitrag von luto9 in 2 Sätzen auf Deutsch schreiben?
Danke im vorraus.
Newmann8

[JS222]

40 % MISE !!!!!!!!!!

10:58:53 AM Bid 0.1 10000 Nasdaq NM
10:58:50 AM Trade (at Bid) 0.1 1000 Nasdaq NM
10:58:24 AM Bid 0.1 1000 Nasdaq NM
10:58:16 AM Bid 0.1 12100 Nasdaq NM
10:58:07 AM Bid 0.1 11100 Nasdaq NM
10:58:05 AM Ask 0.11 1100 Nasdaq NM
10:58:05 AM Trade 0.1 38400 Nasdaq NM
10:58:04 AM Ask 0.13 7600 Nasdaq NM
10:57:57 AM Ask 0.1 38900 Nasdaq NM
10:57:57 AM Trade (at Ask) 0.1 1600 Nasdaq NM
10:57:41 AM Trade (at Ask) 0.1 500 Nasdaq NM
10:57:40 AM Ask 0.1 40500 Nasdaq NM
10:57:35 AM Trade (at Ask) 0.1 500 Nasdaq NM
10:57:35 AM Ask 0.1 41000 Nasdaq NM
10:57:26 AM Trade (at Bid) 0.09 1800 Nasdaq NM
10:56:54 AM Bid 0.09 64000 Nasdaq NM
10:56:04 AM Bid 0.09 55000 Nasdaq NM
10:56:04 AM Trade (at Bid) 0.09 3500 Nasdaq NM
10:56:03 AM Trade (at Bid) 0.09 10000 Nasdaq NM
10:55:56 AM Ask 0.1 41500 Nasdaq NM

most recent back next
10:58:59 AM EDT - Wednesday, August 28, 2002 - data is real-time

JS200

[JS222]

@NEWMANN 8

NEXL - Nexell Therapeutics Inc (NASDAQ NM : NEXL)

--------------------------------------------------------------------------------
Nexell Therapeutics Receives Nasdaq Delisting Notice



WEDNESDAY, AUGUST 28, 2002 07:31 AM

IRVINE, Calif., Aug 28, 2002 (BUSINESS WIRE) -- Nexell Therapeutics Inc. (Nasdaq:NEXL) announced that it received a letter dated August 23, 2002 from The Nasdaq Stock Market indicating that the Company fails to comply with the $1.00 minimum bid price and $5,000,000 market value of publicly-held shares requirements for continued listing set forth in Marketplace Rules 4450(a)(5) and 4450(a)(2), and, as a result, the Company`s securities -- consisting of its common stock and its publicly-traded warrants (Nasdaq:NEXLW) -- will be delisted from The Nasdaq National Market at the opening of business on September 3, 2002. The failure of the common stock to meet the minimum bid price was first announced by the Company on May 23, 2002.

The Company believes it meets the eligibility criteria to have its securities quoted on the OTC Bulletin Board (OTCBB), and the securities may be quoted on the OTCBB following delisting from the Nasdaq National Market. The OTCBB is a regulated quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter securities. Information regarding the OTCBB can be found on the internet at www.otcbb.com.

MACHINELLE ÜBERSETZUNG


NEXL, Nexell Therapeutics Inc (NASDAQ NM): NEXL,

--------------------------------------------------------------------------------
Nexell-Therapeutik erhält Nasdaq, der Benachrichtigung löscht,



MITTWOCH 28. AUGUST 2002 07:31 ist

IRVINE, Calif., 28. August 2002 GESCHÄFTS-DRAHT, Nexell Therapeutics Inc. (Nasdaq:NEXL) verkündete, daß es erhielt, ging ein Brief mit 23. August 2002 von Der Nasdaq-Börse, die zeigt, aus, daß sich die Gesellschaft nicht Anforderungen nach dem $1.00 Minimumsangebotspreis und $5,000,000 Marktwert öffentlich gehaltener Anteile richtet, denn setzte fort, Regeln 4450(a)(5 und 4450(a)(2, hervor in Marktplatz Satz aufzuführen, und, als ein Ergebnis, die Sicherheiten der Gesellschaft, das aus seinem gewöhnlichen Vorrat und seinen öffentlich getauschten Garantien (Nasdaq:NEXLW) besteht, wird am 3. September 2002 von The Nasdaq National-Markt bei der Öffnung des Unternehmens gelöscht werden. Der Mißerfolg des gewöhnlichen Vorrates, den Minimumsangebotspreis zu treffen, wurde am 23. Mai 2002 zuerst von der Gesellschaft verkündet.

Die Gesellschaft glaubt, daß es die Berechtigungskriterien trifft, um seine Sicherheiten auf der OTC Anschlagtafel (OTCBB) zitieren zu lassen, und die Sicherheiten werden vielleicht auf der OTCBB-Gefolgschaft zitiert, die vom Nasdaq National-Markt löscht. Der OTCBB ist ein regulierter Zitatendienst, den Demonstrationen-Echtzeit zitiert, letzte-Verkauf-Preise, und Volumeninformationen in rezeptfreie Sicherheiten. Informationen hinsichtlich des OTCBB kann auf das Internet bei www.otcbb.com gefunden werden.


JS200

[Newman8]

@ JS222
Vielen Dank!
Ist ja eigentlich nichts neues,dass Nexell an die OTC muss!
Mal schauen was dort abgeht!
Newmann8

[xoma]

Leider doch nicht gerettet - Es gibt noch 0,05$ !

Nexell Therapeutics Announces Plan of Liquidation and Dissolution
07:30 EDT Thursday, October 17, 2002

IRVINE, Calif.--(BUSINESS WIRE)--Oct. 17, 2002--Nexell Therapeutics Inc. (OTCBB:NEXL) announced today that its board of directors adopted a plan to liquidate and dissolve the Company. Based upon current information, the Company anticipates that a cash distribution to common stockholders, which will exclude Baxter Healthcare Corporation ("Baxter") and its affiliates, will be $0.05 per share. Although the Company is unable to predict the precise timing of such distribution it hopes to make the distribution prior to year end. In order to be eligible to receive the distribution, a stockholder must be a holder of record of common stock on the record date set by the Board of Directors for such distribution, which is expected to be the date the Company files its certificate of dissolution with the State of Delaware.
In reaching its determination that the plan of liquidation and dissolution is in the best interests of the Company, the Board of Directors considered a number of factors. As previously disclosed, on May 15, 2002, the Board had authorized management to immediately begin an orderly wind up of operations. Since then the Company considered alternatives available to it in effecting the wind up, including dissolution under Delaware law or liquidation or reorganization under the Federal bankruptcy code. In any such procedure, in light of the liquidation preference of the Company`s outstanding Series A and Series B Preferred Stock in the aggregate amount of approximately $151 million, there would be no remaining value available for distribution to the holders of common stock. After discussions with Baxter and its affiliates, which will hold all of the preferred stock, such holders have agreed to consent to a cash distribution to the holders of common stock in connection with the liquidation and dissolution of the Company under Delaware law.
As a Delaware corporation, the Company must obtain stockholder approval for the plan of liquidation and dissolution. The Company and Baxter have entered into an agreement pursuant to which: (i) Baxter and certain of its affiliates have agreed to acquire from the Company`s holders of Series B Preferred Stock such preferred stock, (ii) Baxter and its affiliates will accelerate the pre-existing put of their stock to Baxter International Inc., (iii) Baxter and its affiliates will convert a portion of such stock sufficient to give them ownership of a majority of the outstanding shares of common stock, and (iv) Baxter and its affiliates will then, as majority holders of common stock, approve the plan of liquidation and dissolution by written consent. The put was granted by Baxter International Inc. in November 1999 in connection with the Company`s issuance of the Series B Preferred Stock. Baxter currently owns approximately 17% of the Company`s common stock.
As a common stockholder Baxter will waive its right to the $0.05 per share distribution. As the then sole preferred stockholders Baxter and its affiliates will receive substantially all of the remaining assets of the Company, other than a contingency reserve to satisfy current and anticipated liabilities, in partial satisfaction of their liquidation preference. Pursuant to the plan of liquidation and dissolution, the Company will establish a liquidating trust by year end to which will be contributed any assets not distributed to the stockholders. In connection with the plan of liquidation and dissolution, the Company will file with the SEC an information statement, which will be mailed to stockholders following its filing with the SEC. Investors and security holders are urged to read this document as it contains important information about the plan of liquidation and dissolution and related matters. After it is filed, investors and security holders may obtain copies of the document free of charge from the SEC`s website at www.sec.gov. No proxies will be solicited from Company stockholders with respect to the plan of liquidation and dissolution.
Effective October 17, 2002, and after the adoption by the Board of Directors of the plan of liquidation and dissolution, Victor W. Schmitt was appointed by the Board of Directors to be a director of the Company. Mr. Schmitt, who formerly was a director from December 1997 until May 10, 2002, is an employee of Baxter. It is anticipated that Innovir Laboratories, Inc., a majority owned subsidiary of the Company, will be liquidated in the near future. As a result of the liquidation preference held by the Company as the sole holder of preferred stock of Innovir, it is not expected that there will be any assets available to distribute to the holders of common stock of Innovir.

Nexell Therapeutics Inc.

Located in Irvine, California, Nexell Therapeutics Inc. is a biotechnology company that was focused on the modification or enhancement of human immune function and blood cell formation utilizing adult hematopoietic (blood-forming) stem cells and other specially prepared cell populations. Nexell was developing proprietary cell-based therapies that address major unmet medical needs, including treatments for genetic blood disorders, autoimmune diseases, and cancer. The Company is currently in the process of winding down operations.

This release contains forward-looking statements which are subject to certain risks and uncertainties that could cause actual results to differ materially from current expectations. Such risks and uncertainties include: the Company`s ability to effect an orderly wind down of its operations and to implement the plan of liquidation and dissolution in a timely manner; the Company`s ability to resolve any claims against it; the Company`s ability to sell certain of its remaining assets to generate cash to satisfy its obligations; the Company`s ability to maintain sufficient cash which could be distributed to its stockholders; the Company`s ability to retain the services of key employees or consultants to complete the wind-down; the Company`s obligation to incur the expenses of complying with public company reporting requirements; the substantial dilution to common stockholders in the event that all or a portion of the Company`s two series of Preferred Stock are converted to Common Stock; and any additional factors described from time to time in the Company`s filings with the SEC. These forward-looking statements represent the Company`s judgment as of the date of this release. The Company disclaims any intent or obligation to update these forward-looking statements.


Copyright © 2002, Business Wire